157 related articles for article (PubMed ID: 16920751)
21. Pulmonary artery hypertension as the presenting feature of systemic sclerosis sine scleroderma.
Pauling JD; Gunawardena H; Coghlan JG; Easaw J; Suntharalingam J; McHugh NJ
Rheumatology (Oxford); 2008 Sep; 47(9):1431-2. PubMed ID: 18603658
[No Abstract] [Full Text] [Related]
22. Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension.
Dorfmüller P; Montani D; Humbert M
Eur Respir J; 2010 Jan; 35(1):6-8. PubMed ID: 20044455
[No Abstract] [Full Text] [Related]
23. Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension.
Correale M; Montrone D; Biase MD; Brunetti ND
Clin Res Cardiol; 2012 Jul; 101(7):593-4. PubMed ID: 22383181
[No Abstract] [Full Text] [Related]
24. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma.
Steen V
Arthritis Rheum; 2005 Dec; 52(12):3698-700. PubMed ID: 16320319
[No Abstract] [Full Text] [Related]
25. An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?
Minai O
Lupus; 2009 Jan; 18(1):92. PubMed ID: 19074176
[No Abstract] [Full Text] [Related]
26. [Pulmonary hypertension in patients with systemic sclerosis].
Ciurzyński M; Bienias P; Pruszczyk P
Kardiol Pol; 2007 Aug; 65(8):994-1000. PubMed ID: 17853323
[No Abstract] [Full Text] [Related]
27. Management of systemic sclerosis.
Lim IG; Schrieber L
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):953-7. PubMed ID: 12455189
[No Abstract] [Full Text] [Related]
28. Pulmonary arterial hypertension in systemic sclerosis: a distinctive endotheliopathy?
Orfanos SE; Langleben D
Eur Respir J; 2010 Jan; 35(1):223-4. PubMed ID: 20044465
[No Abstract] [Full Text] [Related]
29. [Pulmonary arterial hypertension in collagen disease: experiences of the German Network for Systemic Scleroderma].
Hunzelmann N; Riemekasten G
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S325-7. PubMed ID: 17139598
[TBL] [Abstract][Full Text] [Related]
30. [An up date on pulmonary hypertension related to systemic sclerosis].
Kowal-Bielecka O; Sulik A; Sierakowski S
Przegl Lek; 2005; 62(8):813-7. PubMed ID: 16521504
[TBL] [Abstract][Full Text] [Related]
31. [Drug therapy of primary and secondary pulmonary hypertension].
Olschewski H
Herz; 2002 Aug; 27(5):463-7. PubMed ID: 12365287
[No Abstract] [Full Text] [Related]
32. Limitations of the findings regarding the relationship between N-terminal pro-brain natriuretic peptide and systemic sclerosis-related pulmonary arterial hypertension: comment on the article by Allanore et al.
Dimitroulas T; Giannakoulas G; Karvounis H; Settas L
Arthritis Rheum; 2008 Jul; 58(7):2215-6; author reply 2216. PubMed ID: 18576342
[No Abstract] [Full Text] [Related]
33. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
[TBL] [Abstract][Full Text] [Related]
34. Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis?
Steen VD; Champion H
Int J Clin Pract Suppl; 2011 Jan; (169):1-3. PubMed ID: 21176008
[No Abstract] [Full Text] [Related]
35. Outcome measurements in scleroderma: results from a delphi exercise.
Gazi H; Pope JE; Clements P; Medsger TA; Martin RW; Merkel PA; Kahaleh B; Wollheim FA; Baron M; Csuka ME; Emery P; Belch JF; Hayat S; Lally EV; Korn JH; Czirjak L; Herrick A; Voskuyl AE; Bruehlmann P; Inanc M; Furst DE; Black C; Ellman MH; Moreland LW; Rothfield NF; Hsu V; Mayes M; McKown KM; Krieg T; Siebold JR
J Rheumatol; 2007 Mar; 34(3):501-9. PubMed ID: 17299843
[TBL] [Abstract][Full Text] [Related]
36. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy.
Dimopoulos K; Peset A; Gatzoulis MA
Int J Cardiol; 2008 Sep; 129(2):163-71. PubMed ID: 18367267
[TBL] [Abstract][Full Text] [Related]
37. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Avouac J; Wipff J; Kahan A; Allanore Y
Ann Rheum Dis; 2008 Jun; 67(6):808-14. PubMed ID: 17901091
[TBL] [Abstract][Full Text] [Related]
38. Therapy of pulmonary arterial hypertension in systemic sclerosis: an update.
Denton CP; Nihtyanova SI
Curr Rheumatol Rep; 2007 May; 9(2):158-64. PubMed ID: 17502047
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes in pulmonary arterial hypertension.
Thenappan T; Palevsky HI
Int J Clin Pract Suppl; 2009 Sep; (162):42-4. PubMed ID: 19624799
[No Abstract] [Full Text] [Related]
40. Children deserve the same rights we do: the need for paediatric pulmonary arterial hypertension clinical drug development.
Barst RJ
Heart; 2010 Sep; 96(17):1337-8. PubMed ID: 20801850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
